Te­va charged — again — for al­leged role in fix­ing gener­ic drug prices, this time by the De­part­ment of Jus­tice

The dock­et keeps pil­ing up for Te­va.

Late Tues­day, the Jus­tice De­part­ment be­came the lat­est in a long string of pros­e­cu­tors to ac­cuse the Is­raeli drug­mak­er of malfea­sance, charg­ing the com­pa­ny with three counts of con­spir­ing to fix gener­ic drug prices. These new al­le­ga­tions come just a week af­ter Te­va $TE­VA was sued by New York over its role in the opi­oid epi­dem­ic and by fed­er­al pros­e­cu­tors over its pur­port­ed scheme to de­fraud Medicare.

“To­day’s charge reaf­firms that no com­pa­ny is too big to be pros­e­cut­ed for its role in con­spir­a­cies that led to sub­stan­tial­ly high­er prices for gener­ic drugs re­lied on by mil­lions of Amer­i­cans,” said Makan Del­rahim, As­sis­tant At­tor­ney Gen­er­al of the DoJ’s An­titrust Di­vi­sion in a state­ment. “The di­vi­sion will con­tin­ue … to en­sure that com­pa­nies that bla­tant­ly cheat con­sumers of the ben­e­fits of free mar­kets are pros­e­cut­ed to the full ex­tent of the law.”

Pre-mar­ket trad­ing showed a mut­ed re­ac­tion from in­vestors, with Te­va shares down about 3% ear­ly Wednes­day.

Te­va is the sev­enth com­pa­ny to be charged for rig­ging gener­ic drug prices, the de­part­ment added. Five of the cas­es were set­tled in de­ferred pros­e­cu­tion agree­ments, while the sixth is await­ing a tri­al.

Each of the counts in­clud­ed in Tues­day’s fil­ing car­ries a max­i­mum of $100 mil­lion in penal­ties.

Ac­cord­ing to the DoJ re­lease, Te­va par­tic­i­pat­ed in three sep­a­rate price fix­ing plots from at least as ear­ly as May 2013 and through at least De­cem­ber 2015. The most promi­nent drug in­volved was pravas­tatin, a com­mon treat­ment used to low­er cho­les­terol and re­duce the risks of heart at­tack and stroke.

Te­va col­lud­ed with In­di­an gener­ic man­u­fac­tur­er Glen­mark, Cana­di­an phar­ma Apo­tex and oth­er un­named co-con­spir­a­tors, the DoJ ac­cus­es, to raise prices of pravas­tatin and oth­er gener­ic drugs. Apo­tex set­tled with pros­e­cu­tors and agreed to pay a $24.1 mil­lion fine in May, while a grand ju­ry in­dict­ed Glen­mark in Ju­ly.

Ad­di­tion­al­ly, the Is­raeli phar­ma stands ac­cused of en­gag­ing in two oth­er al­leged schemes with Taro Phar­ma­ceu­ti­cals and No­var­tis’ gener­ics unit San­doz, re­spec­tive­ly. Taro and San­doz both ad­mit­ted to their roles in the plots ear­li­er this year and paid fines of about $200 mil­lion each. Top ex­ec­u­tives from the com­pa­nies, in­clud­ing a for­mer se­nior No­var­tis ex­ec­u­tive, were al­so pre­vi­ous­ly charged.

Le­gal pro­ceed­ings are adding up for Te­va, as the Medicare case brought last week blamed the com­pa­ny for pay­ing over $300 mil­lion in kick­backs to sep­a­rate foun­da­tions be­tween 2006 and 2015. That re­sult­ed in the quin­tu­pling of the cost of Co­pax­one, a for­mer cash cow that peaked at $3 bil­lion in year­ly sales.

The New York law­suit al­leged more ne­far­i­ous mis­deeds on Te­va’s part, ac­cus­ing that the com­pa­ny “know­ing­ly fur­thered false nar­ra­tives” in or­der to boost sales and mis­rep­re­sent­ed the risks of fen­tanyl-based drugs for off-la­bel use.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA have vowed not to let politics get in the way of science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped health agencies under his purview — including the FDA — of their rulemaking ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Eli Lilly CSO Dan Skovronsky (file photo)

#ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Greg Friberg (File photo)

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of 10 evaluable non-small cell lung cancer patients demonstrating a response to the drug.

After decades of failure targeting KRAS, sotorasib offered the first positive look at a new approach that promised to open a door to a whole new approach by targeting a particular mutation to a big target that had remained “undruggable” for decades.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mutant non-small cell lung cancer has turned up some promising — although decidedly early — results, fueling the idea that there’s yet room to one up on third-generation tyrosine kinase inhibitors.

Twenty out of 20 advanced NSCLC patients had a response after taking a combination of an in-house TKI dubbed lazertinib and amivantamab, a bispecific antibody targeting both EGFR and cMET engineered on partner Genmab’s platform, J&J reported at ESMO. All were treatment-naïve, and none has seen their cancer progress at a median follow-up of seven months.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Any $12 billion megablockbuster in the portfolio tends to overshadow everything else in the pipeline. Which is something Merck can tell you a little bit about.

Keytruda not only dominates the PD-(L)1 field, it looms over everything Merck does, to the point some analysts wonder if Merck is a one-trick pony.

There’s no shortage of Keytruda data on display at ESMO this weekend, but now the focus is shifting to the future role of new drugs and combos in maintaining that lead position for years to come. And the pharma giant has a special focus for 3 early-stage efforts where Roger Perlmutter’s oncology team is placing some big bets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

When AstraZeneca trumpeted “momentous” and “transformative” results for Tagrisso earlier this year at ASCO, some practitioners threw cold water on the ADAURA fervor. Sure, the disease-free survival data look good, but overall survival is the endpoint that matters when it comes to choosing adjuvant therapy for non-small cell lung cancer patients, the experts said.

The OS data still aren’t here, but AstraZeneca is back at ESMO to bolster their case with a look at brain metastasis data.

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.